Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) Short Interest Update

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) was the target of a large decrease in short interest in the month of May. As of May 15th, there was short interest totaling 19,000 shares, a decrease of 59.4% from the April 30th total of 46,815 shares. Based on an average trading volume of 85,097 shares, the short-interest ratio is currently 0.2 days. Currently, 0.7% of the shares of the company are short sold.

Institutional Trading of Cardio Diagnostics

Several large investors have recently bought and sold shares of CDIO. Citadel Advisors LLC acquired a new stake in Cardio Diagnostics in the third quarter valued at about $79,000. DRW Securities LLC boosted its stake in Cardio Diagnostics by 122.8% in the fourth quarter. DRW Securities LLC now owns 40,463 shares of the company’s stock valued at $110,000 after buying an additional 22,298 shares in the last quarter. Finally, Renaissance Technologies LLC acquired a new stake in Cardio Diagnostics in the first quarter valued at about $30,000. 8.06% of the stock is owned by institutional investors and hedge funds.

Cardio Diagnostics Price Performance

CDIO stock opened at $2.13 on Tuesday. The stock has a market capitalization of $6.30 million, a price-to-earnings ratio of -0.63 and a beta of 2.25. The business’s fifty day moving average price is $1.85 and its two-hundred day moving average price is $2.50. Cardio Diagnostics has a fifty-two week low of $0.97 and a fifty-two week high of $7.91.

Cardio Diagnostics (NASDAQ:CDIO) last posted its quarterly earnings data on Friday, May 15th. The company reported ($0.63) earnings per share for the quarter. Cardio Diagnostics had a negative return on equity of 78.82% and a negative net margin of 36,950.00%.

Analyst Ratings Changes

Separately, Wall Street Zen upgraded Cardio Diagnostics to a “hold” rating in a research note on Saturday, March 21st. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, Cardio Diagnostics has an average rating of “Sell”.

About Cardio Diagnostics

Cardio Diagnostics Holdings, Inc develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc was founded in 2017 and is headquartered in Chicago, Illinois.